Companies are leveraging artificial intelligence to create an innovative platform replicating the human immune system in a petri dish. This groundbreaking approach aims to accelerate drug development and facilitate safer clinical trials.
Traditionally, the drug development process has been plagued by complexities, high costs, and uncertainties surrounding a drug’s potential for success. Particularly in nervous system disorders, the unknown pathophysiology makes identifying suitable targets a daunting challenge. Moreover, animal models used for drug testing often fail to replicate the entirety of a human disorder or disease accurately, and their responses to drugs may differ from those of the human body.
However, AI is paving the way for faster, more cost-effective pharmaceutical solutions. These AI models can identify intricate patterns and relationships within data that are difficult for humans to discern, enabling more precise and targeted drug development.
By combining AI with their expertise, startups are developing platforms that offer deeper insights into human physiology, enhancing our understanding and facilitating more informed drug development.
This article explores 10 companies that use AI technology to enhance drug development in 2026.
1. Galixir
| Founding Year | 2019 |
| Headquarters | Beijing, China |
| Total Funding Amount | $10M |
| Last Funding Round/Amount | Series A |
| Website | galixir.com |
Galixir leverages artificial intelligence to accelerate drug research and development. It focuses on hard-to-develop drugs and unmet clinical needs.
They’ve developed two main products: Pyxir® and M13.
Pyxir®, its drug discovery platform, provides end-to-end solutions for preclinical drug discovery by blending advanced AI technologies with domain expertise in computational chemistry, medicinal chemistry, and biology.
M1, the AI-driven intelligent computing platform, is independently developed by Galixir for drug discovery. It combines AI with classical physics principles to advance classical molecular modeling methods and accurately describe interactions between molecules and proteins.
The startup has also developed the world’s first deep learning framework, TankBind, that simultaneously predicts both small-molecule drug binding conformation and binding affinity.
The CEO, Chengtao Li, holds a Ph.D. and a Master’s in Computer Science from the Massachusetts Institute of Technology (MIT). Before Galixir, he worked as a Research Assistant at MIT and had internships at Microsoft Research.
Galixir has raised a total of $10M in funding. Their latest funding was raised from a Series A round on Dec 29, 2020.
Related Read
2. Model Medicines
| Founding Year | 2019 |
| Headquarters | California, United States |
| Total Funding Amount | $4.1M |
| Last Funding Round/Amount | Early Stage VC, $950K |
| Website | modelmedicines.com |
Model Medicines is an AI-driven human health company that uses AI to model chemistry and human biology, accelerating the creation of life-changing drugs. Founded in 2019, the startup has developed a product called GALILEO™ that has identified 192 compounds for 26 targets. Their lead asset is a pan-antiviral candidate, MDL-001, whose antiviral activity was discovered by Model Medicines’ GALILEO™ Platform.
The CEO, Daniel Haders II, has 20+ years of experience in healthcare as a scientist and entrepreneur. Before Model Medicines, Daniel launched the Nex Cubed Digital Health Accelerator, which was recognized as one of the top 10 global digital health accelerators.
Model Medicines has raised a total of $4.1M in funding. This was a Seed round raised on Feb 1, 2021.
3. Parallel Bio
| Founding Year | 2020 |
| Headquarters | Massachusetts, United States |
| Total Funding Amount | $4.6M |
| Last Funding Round/Amount | Seed, $4.3M |
| Website | www.parallel.bio |
Parallel Bio develops models of human immune system components to accelerate the discovery and development of immunotherapies, cell therapies, antibody therapies, and vaccines.
Its platform combines human immune organoids with computational methods to generate insights into health and diseases.
The platform replicates the human immune system in a dish across populations to discover cures faster. Drugs need no longer be tested on mice. This system enables the discovery and development of drugs that effectively treat patients. Additionally, it gives insights into how well they perform across an entire population.
The CEO, Robert M. DiFazio, is a Stanford graduate with a Ph.D. in Immunology of Infectious Diseases from the University of Pittsburgh School of Medicine.
Parallel Bio has raised a total of $4.6M in funding. Their latest funding was raised from a Seed round on Dec 20, 2022.
4. Arpeggio Bio
| Founding Year | 2017 |
| Headquarters | Colorado, United States |
| Total Funding Amount | $20.4M |
| Last Funding Round/Amount | Series A, $17M |
| Website | www.arpeggiobio.com |
Arpeggio Bio uses machine learning and RNA to make drugs. The company’s solution uses AI to interpret RNA time-series data to reconstruct signaling pathways.
They have built the world’s largest database of nascent RNA sequences. This database guides drug development by predicting whether a molecule will be toxic or beneficial to a patient.
Arpeggio Bio’s technology enables rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development.
The Founder & CEO, Joey Azofeifa, has nearly a decade of experience as a data scientist, working with biologists to tackle complex drug-development challenges.
Arpeggio Bio is a Y Combinator company and has raised over 20M in venture funding from firms such as Builders VC and Khosla Ventures.
5. Nabla Bio
| Founding Year | 2020 |
| Headquarters | Greater Denver Area, Western US |
| Total Funding Amount | $11.3M |
| Last Funding Round/Amount | Seed, $11M |
| Website | www.nabla.bio |
Nabla Bio uses artificial intelligence to design and refine next-generation therapeutic antibodies.
Its platform, Autoverse, enables the rapid discovery of previously unattainable protein variants. The platform combines high-end protein language modeling, a branch of AI-driven protein modeling that the CEO co-founded, with a high-throughput multiplex antibody analysis technology.
The platform’s ultimate goal is to create new antibody drugs specifically engineered to address challenging clinical targets and be commercially viable.
Surge Biswas, Ph.D., the CEO, is a scientist with 10+ years of experience applying synthetic biology and machine learning to engineer microbiomes and proteins.
Nabla Bio has raised a total of $11.3M in funding. Their latest funding was from a seed round on December 6, 2021.
6. Elnora AI
| Founding Year | 2023 |
| Headquarters | Tallinn, Harjumaa, Estonia |
| Total Funding Amount | $71.5K |
| Last Funding Round/Amount | Angel Investment/$71.5K |
| Website | https://www.elnora.ai/ |
Traditional antiviral drug development is costly and time-consuming, often taking over a decade and costing billions of dollars. It also has a high failure rate. Moreover, Rapid virus mutation rates and the limited effectiveness of existing treatments exacerbated these challenges. This inefficiency stems from the direct targeting of viruses, which mutate rapidly and render treatments ineffective.
To tackle this problem, Elnora AI has developed an AI-driven platform that targets host cells rather than the viruses themselves. This innovative approach leverages machine learning to analyze vast amounts of biological data, identifying potential therapeutic targets within host cells that are less likely to mutate.
The startup platform, Elnora, integrates data from multiple sources, including drug databases, scientific literature, and omics data, and presents it in an interactive, user-friendly knowledge graph.
Elnora accelerates the research process significantly while reducing costs. By focusing on host cells, the platform increases the likelihood of clinical success and reduces susceptibility to viral mutations.
Carmen Kivisild is the co-founder and CEO of this startup. She holds a PhD in Neuroscience from University College London (UCL) and worked as a Postdoctoral Researcher at King’s College London.
Carmen co-founded Koolituskeskus PracticeGate and led it as Chief Business Development Officer (CBDO) and lecturer for 8+ Years.
Elnora raised its latest funding of $71.5K from an Angel investment round on 21 December 2023. It also received an Enterprise Estonia Support (ESS) equity-free grant of 50,000 EUR from the European Regional Development Fund.
7. Maven Bio
| Founding Year | 2023 |
| Headquarters | Boston, Massachusetts, US |
| Total Funding Amount | 500K |
| Last Funding Round/Amount | Pre-Seed/500K |
| Website | https://www.mavenbio.io/ |
The traditional process of evaluating therapeutic opportunities within the biopharmaceutical industry is inefficient. It heavily relies on consultants and fragmented information, often resulting in incomplete and delayed analyses. This approach contributes to the high failure rate in clinical development, with approximately 169 drugs failing annually (~60 approved) due to business and commercial reasons.
Maven Bio has developed an AI-enabled commercial intelligence platform to solve these issues and streamline the evaluation process. The platform integrates document search, review, and analysis workflows into a single workspace. It allows corporate development teams to construct comprehensive deal landscapes and perform comparative analyses efficiently.
This platform provides evidence-based insights using AI to facilitate faster, more informed decision-making. These insights are tailored to the business context.
By leveraging AI, the platform can halve the commercial failure rate, thus increasing the number of drugs approved and available to patients. This Y-combinator-backed startup also provides research and analysis on the latest biopharma trends.
Michael Brady and Arjun Murthy are the co-founders of this Biopharma AI startup. Arjun holds an MBA from Yale School of Management. Michael attended the University of Pennsylvania for a Master of Computer and Information Technology.
Arjun worked as a Strategy Business Development Manager with EP Dynamics for 3+ years. He was also an associate at McKinsey & Company for approximately 2 years.
Michael started his career as an analyst with Innosight and later worked as an Associate Director of Corporate Strategy for Valo.
Maven Bio raised its latest pre-seed funding round for 500K on 6 September 2023 from Y-Combinator.
Other startups, such as Persist AI, Lavo Life Sciences, and Vevo Therapeutics, are speeding up and simplifying therapeutic development.
Related Read
8. Olio Labs
| Founding Year | 2023 |
| Headquarters | California, US |
| Total Funding Amount | $4.5 Million |
| Last Funding Round/Amount | Pre-Seed/$4.5 Million |
| Website | https://oliolabs.co/ |
Combination therapeutics involves optimizing the use of multiple therapeutic agents to treat diseases. Traditional methods for discovering these combinations are inefficient and time-consuming, often leading to treatments with significant side effects.
The Y-combinator-backed startup Olio Labs has developed an AI-driven platform that leverages machine learning to design and test trillions of drug combinations. Its Compute-Experiment enables rapid in silico testing and the identification of optimal combinations with enhanced efficacy and fewer side effects.
Olio Labs’ approach focuses on understanding the complex interactions of thousands of proteins in the human body rather than targeting just one or two, which is common in traditional drug development.
The startup technology accelerates the combination therapeutics discovery process four times and reduces associated costs by 90%. Its advanced AI algorithms predict and optimize the best combination therapies based on real-world biological data.
Olio Labs has developed a lead combination therapeutic that reduces appetite and associated nausea in animal models. The drug aims to outperform leading obesity drugs like Ozempic.
David Tingley (CEO) and Tom Roseberry (CTO) are the founders and leaders of this Biopharma AI startup. They are both venture partners at Pioneer Fund.
David holds a PhD in neuroscience from New York University and completed his postdoctoral research at Harvard University. He has 13+ years of experience in neuroscience, including 2 years as a Postdoctoral Scientist at BIDMC.
His experience includes more than 15 scientific articles. He also uncovered a link between oscillations in brain activity and glucose metabolism.
Tom holds a BS in Mechanical Engineering from Boston University and a PhD in Neuroscience from the University of California. He started his career as a Mechanical Engineer at Electroimpact and, after completing his PhD, worked on the technical staff at Neuralink.
In various executive roles, Tom was part of Cellular Longevity, Inc., dba Loyal.
Olio Labs completed its latest pre-seed funding round on 01 August 2023. It raised $4.5 million from ZAKA VC, Y Combinator, Unpopular Ventures, and Pioneer Fund.
9. Yoneda Labs
| Founding Year | 2023 |
| Headquarters | San Francisco, California, US |
| Total Funding Amount | $4.5 Millon |
| Last Funding Round/Amount | Seed/$4.5 Millon |
| Website | https://www.yonedalabs.com/ |
Chemists spend weeks or even months determining the best reaction conditions through trial and error, which can delay the development of new drugs and materials. Traditional processes are inefficient and costly when optimizing chemical reactions in the biopharmaceutical and chemical manufacturing industries.
Yoneda Labs has developed two key AI-driven products to address these issues: Yoneda Optimize and Yoneda Predict.
Yoneda Optimize is a desktop application that helps chemists identify and optimize reaction conditions, such as temperature, concentration, and catalyst, in days rather than weeks.
Yoneda Predict provides direct reaction conditions without the need for wet-lab experimentation, helping eliminate guesswork in chemical synthesis.
These Biopharma AI tools leverage advanced machine learning algorithms to predict optimal reaction parameters using a curated database of chemical reactions and high-throughput experimentation (HTE) data.
Yoneda Labs’ technology significantly reduces the time and cost of chemical synthesis. Its AI models have suggested reaction conditions achieving yields within 20% of the best possible, optimizing processes that would otherwise require extensive and repetitive testing.
Michał Mgeładze-Arciuch is the co-founder and CEO of this startup. Michal gained industry experience as a software engineer through internships at Z-Tech Control Systems Ltd and Jane Street. He was a full-time AI researcher at the Center for Human-Compatible AI (CHAI) at Berkeley.
His alma mater is the University of Cambridge, where he earned a Bachelor of Arts in Computer Science. He also attended Cambridge Judge Business School, where he completed a two-year Accelerate Program in Business/Entrepreneurship.
Yoneda Labs raised its latest seed funding round on 26 April 2024 for $4.5 Million. Khosla Ventures led it, and participants include 500 Emerging Europe, 468 Capital, and Y Combinator.
The startup plans to use the funding to acquire robotic automation devices for chemical reactions. It will help create the training data for the startup’s model.
10. Metanovas Biotech
| Founding Year | 2021 |
| Headquarters | Mountain View, California, US |
| Total Funding Amount | $10 Million |
| Last Funding Round/Amount | Seed/$10 Million |
| Website | https://www.metanovas.com/ |
Traditional drug discovery processes are often time-consuming, expensive, and have high failure rates. This is due to the complexity of biological systems and the trial-and-error nature of current methodologies. Metanovas Biotech is tackling significant inefficiencies and high costs associated with identifying novel drug targets and optimizing therapeutic compounds.
The startup has developed a suite of AI-enabled technologies that streamline and enhance the drug discovery process. Its AI-driven platform integrates machine learning and big data analytics into MetaNLP®, MetaKG®, MetaPep®, and MetaOmics®.
This platform helps discover novel disease targets, screen potential drugs, repurpose existing medications for new indications, and predict ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. It leverages advanced algorithms to analyze vast datasets, providing actionable insights that accelerate the development of effective therapies.
The startup has developed products for the healthcare, functional foods, and cosmetics industries using its AI technology. Its strategic partners include global brands like L’Oréal, Beiersdorf, Haleon, Takeda, and Unilever.
Metanovas Biotech’s AI-driven technology significantly reduces the time and cost of drug discovery. Additionally, its technology increases the likelihood of success in later stages of drug development, potentially reducing overall costs by millions of dollars.
The AI-driven approach also enhances precision in predicting how compounds will behave in the human body, increasing the efficiency and safety of new therapies.
Meijie Wang is the co-founder and CEO of this startup. He has experience working with companies such as NIVIDEA (AI Infrastructure Software Engineer), Olympus Corporation (R&D Software Engineer), and DawnLight.
Wang started his professional career as a co-founder of Studio Qfun, which focused on Virtual Reality/Immersive Gaming experiences. He holds an MS in Computer Software and Media Applications from Worcester Polytechnic Institute (WPI) and is a dropout from Stanford University.
The latest seed funding round of Metanovas Biotech was on 31 March 2022 for $10 Million.
Partner with these cutting-edge startups to tackle your industry’s toughest challenges and stay ahead of the competition.
Discover how GreyB helps you find similar ventures that perfectly fit your needs:
How Can We Help You?
We support industry-leading R&D and Innovation professionals through complex problems. Describe your challenge, and let us bring clarity and expertise.
